Thyroid Eye Disease Market Top Players - Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Thyroid Eye Disease Market - (By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Thyroid Eye Disease Market is valued at US$ 2.15 billion in 2023, and it is expected to reach US$ 3.31 billion by 2031, with a CAGR of 5.7% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2893

The swelling and inflammation surrounding the eyes are the cause of thyroid eye disease, an autoimmune condition. Graves' orbitopathy or Graves' ophthalmopathy are other names for it. Due to the growing prevalence of thyroid eye disease, it is expected to increase in the coming years. Improved healthcare settings, positive patient compliance percentage, and improvements in autoimmune disease treatment are among the other factors expected to boost the growth of the global thyroid eye disease market. Additionally, the global thyroid eye disease market is anticipated to generate potential revenue opportunities for players due to the high level of disposable income and the expansion of research and development activities. High investments by major actors and new developments in the development of a variety of end-use products have generated lucrative revenue opportunities for major manufacturers and suppliers of thyroid eye disease. The target market is anticipated to experience growth due to favorable government actions that encourage the use of artificial tears & lubricating eye drops to alleviate dehydration.

List of Prominent Players in the Thyroid Eye Disease Market:
• Horizon Therapeutics
• Viridian Therapeutics
• Pierre Fabre/ACELYRIN
• HanAll Biopharma/Harbour BioMed/Immunovant
• Sling Therapeutics
• Other Market Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:
Drivers-
The growing prevalence of thyroid eye disease is a key factor predicted to propel the market growth. Increasing positive patient compliance percentage and improvements in autoimmune disease treatment are other factors expected to contribute significantly to the revenue share in the global thyroid eye disease market. Additionally, the rising research and development activities and increasing investment are other factors expected to augment the growth of the global Thyroid Eye Disease market.

Challenges:
The primary difficulty is the absence of a definitive thyroid eye treatment and insufficient knowledge in emerging nations, which is anticipated to hinder the expansion of the Thyroid Eye Disease market. The substantial expense associated with Thyroid Eye Disease is anticipated to impede the overall expansion of the Thyroid Eye Disease market in the forthcoming years. Due to the COVID-19 pandemic, the incidence of cases has risen, resulting in a global or partial lockdown to enforce social separation. Recent updates indicate that companies are experiencing unparalleled economic losses because of interruptions in global supply chains affecting major participants in the Thyroid Eye Disease industry. Distributors, suppliers, and retailers own goods but are unable to sell, while manufacturers must halt production to address the shutdown.

Regional Trends:
The North American thyroid eye disease market is expected to report a large market revenue share. It is projected to grow at a high CAGR in the near future. The growing prevalence of several thyroid diseases, advancement in treatment options, and increasing R&D activities by prominent players are factors expected to proliferate the growth of the thyroid eye disease market in the region. Also, Europe had a substantial share in the market due to its developed economy as well as growing adoption of the product. This is due to the acceptance of new strategies and methodes by the major players in the thyroid eye disease market. Moreover, the existance of significant market players and increasing collaboration among major players for market penetration in the region provides a chance for growth of the global thyroid eye disease market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2893

Recent Developments:
• In March 2024, ACELYRIN, INC. announced positive proof-of-concept results from a Phase ½ trial of lonigutamab in thyroid eye condition that is now underway. Lonigutamab is a subcutaneous (SC) humanized IgG1 monoclonal antibody that aims the insulin-like growth factor-1 receptor (IGF-1R), a known mechanism of action for thyroid eye disease treatment.

Segmentation of Thyroid Eye Disease Market-
By Marketed Treatment-
• TEPEZZA (Teprotumumab)
By Pipeline Treatment-
• VRDN 001
• VB 421
• Batoclimab
• Linsitnib
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2893

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.